Prelude Therapeutics (PRLD) Change in Acquisitions & Divestments (2022 - 2026)

Prelude Therapeutics (PRLD) has 5 years of Change in Acquisitions & Divestments data on file, last reported at $8.5 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments fell 88.15% year-over-year to $8.5 million; the trailing twelve-month figure through Mar 2026 stood at $91.2 million (down 48.87% YoY), and the FY2025 full-year result was $154.4 million, up 7.48% from the prior year.
• Change in Acquisitions & Divestments grew to $8.5 million in Q1 2026, from $6.4 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $81.4 million in Q3 2022 to a low of $6.4 million in Q4 2025.
• A 5-year average of $41.2 million and a median of $40.1 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• Across the five-year window, Change in Acquisitions & Divestments jumped 95.01% in 2023 and tumbled 88.15% in 2026, its largest moves.
• Tracing PRLD's Change in Acquisitions & Divestments over 5 years: stood at $35.0 million in 2022, then jumped by 95.01% to $68.2 million in 2023, then sank by 56.78% to $29.5 million in 2024, then slumped by 78.3% to $6.4 million in 2025, then soared by 32.8% to $8.5 million in 2026.
• Business Quant data shows PRLD's Change in Acquisitions & Divestments at $8.5 million in Q1 2026, $6.4 million in Q4 2025, and $40.1 million in Q3 2025.